(Total Views: 489)
Posted On: 06/23/2025 4:34:35 PM
Post# of 87125
Re: mikeyt1818 #87029
Ir-Med news via OTC markets news outlet,
https://www.otcmarkets.com/stock/IRME/news
IR-MED Reports Positive Interim Results from U.S. Clinical Study of PressureSafe(TM) for Pressure Injury Assessment Across Diverse Skin Tones
Newsfile Corp.
Newsfile Corp
PressureSafe™, IR-MED's lead product, demonstrated 94% sensitivity in assessing tissue at risk for pressure injuries prior to visible skin breakdown
Technology addresses longstanding disparities in skin assessment, particularly in patients with darker skin tones
Results presented at HCA Healthcare & Galen College of Nursing Research Day; additional data to be featured at a podium session at the 2025 ANCC Magnet/ANE Research Symposium
Rosh Pina, Israel--(Newsfile Corp. - June 23, 2025) - As the U.S. commemorated Juneteenth, last week, IR-MED Inc. (OTCQB: IRME) ("IR-MED" or the "Company"
, a developer of noninvasive artificial intelligence (AI)-powered spectrographic technology to address critical healthcare challenges, today announced positive interim results from its ongoing U.S. clinical study of PressureSafe™, a handheld infrared spectroscopy device for assessment of pressure injuries (PIs), including deep tissue injuries (DTIs) before visible skin breakdown - a breakthrough especially significant for patients with darker skin tones.
Preliminary findings from a study conducted at Methodist Healthcare in San Antonio, Texas, part of HCA Healthcare, encompass 786 scans across 163 anatomical sites, with 61% of participants representing Fitzpatrick skin types IV-VI (darker skin tones). The PressureSafe™ device demonstrated a sensitivity of 94% (Confidence Interval: 0.83-1.00) in assessing tissue status at high risk for Stage 1 pressure injuries and suspected deep tissue injuries (sDTI) before skin breakdown, with no safety concerns reported.
https://www.otcmarkets.com/stock/IRME/news
https://www.otcmarkets.com/stock/IRME/news
IR-MED Reports Positive Interim Results from U.S. Clinical Study of PressureSafe(TM) for Pressure Injury Assessment Across Diverse Skin Tones
Newsfile Corp.
Newsfile Corp
PressureSafe™, IR-MED's lead product, demonstrated 94% sensitivity in assessing tissue at risk for pressure injuries prior to visible skin breakdown
Technology addresses longstanding disparities in skin assessment, particularly in patients with darker skin tones
Results presented at HCA Healthcare & Galen College of Nursing Research Day; additional data to be featured at a podium session at the 2025 ANCC Magnet/ANE Research Symposium
Rosh Pina, Israel--(Newsfile Corp. - June 23, 2025) - As the U.S. commemorated Juneteenth, last week, IR-MED Inc. (OTCQB: IRME) ("IR-MED" or the "Company"
, a developer of noninvasive artificial intelligence (AI)-powered spectrographic technology to address critical healthcare challenges, today announced positive interim results from its ongoing U.S. clinical study of PressureSafe™, a handheld infrared spectroscopy device for assessment of pressure injuries (PIs), including deep tissue injuries (DTIs) before visible skin breakdown - a breakthrough especially significant for patients with darker skin tones. Preliminary findings from a study conducted at Methodist Healthcare in San Antonio, Texas, part of HCA Healthcare, encompass 786 scans across 163 anatomical sites, with 61% of participants representing Fitzpatrick skin types IV-VI (darker skin tones). The PressureSafe™ device demonstrated a sensitivity of 94% (Confidence Interval: 0.83-1.00) in assessing tissue status at high risk for Stage 1 pressure injuries and suspected deep tissue injuries (sDTI) before skin breakdown, with no safety concerns reported.
https://www.otcmarkets.com/stock/IRME/news
(6)
(1)
